Back to top
more

Acer Therapeutics (ACER)

(Delayed Data from OTC)

$0.66 USD

0.66
NA

0.00 (0.00%)

Updated Nov 20, 2023 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (154 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.

KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study

by Zacks Equity Research

KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.

Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug

by Zacks Equity Research

Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.

Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval

by Zacks Equity Research

Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.

Philips (PHG) to Showcase New Innovations & Cardiac Solutions

by Zacks Equity Research

Philips (PHG) is launching cardiac solutions to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers.

Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

by Zacks Equity Research

Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.

Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study

by Zacks Equity Research

Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.

Philips (PHG) Expands Partnership to Build Angio CT Solution

by Zacks Equity Research

Philips (PHG) is building the world's first spectral detector angio CT solution by forging an alliance with the Leiden University Medical Center.

Philips (PHG) Alerts Users of Health Hazards of Therapy Masks

by Zacks Equity Research

Philips (PHG) cautions customers against health hazards faced by the users of CPAP or Bi-Level PAP therapy masks with magnetic headgear.

    New Strong Sell Stocks for July 28th

    by Zacks Equity Research

    ACER, BAK, and CJPRY have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2022.

    New Strong Sell Stocks for July 15th

    by Zacks Equity Research

    ACER, HMN, and STT have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2022.

    New Strong Sell Stocks for July 8th

    by Zacks Equity Research

    ACER, CAH, and DRI have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2022.

    New Strong Sell Stocks for June 28th

    by Zacks Equity Research

    ACER, BA, and LOB have been added to the Zacks Rank #5 (Strong Sell) List on June 28, 2022.

    New Strong Sell Stocks for June 23rd

    by Zacks Equity Research

    ACER, PRG, and ALX have been added to the Zacks Rank #5 (Strong Sell) List on June 23, 2022.

    Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More

    by Zacks Equity Research

    Regulatory and other updates from Moderna (MRNA) and Acer (ACER) are a few key highlights from the biotech sector during the past week.

    Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug

    by Zacks Equity Research

    Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.

      New Strong Sell Stocks for June 21st

      by Zacks Equity Research

      ALYA, ALGN, and ACER have been added to the Zacks Rank #5 (Strong Sell) List on June 21, 2022.

      New Strong Sell Stocks for June 15th

      by Zacks Equity Research

      ACER, AHCHY, and AVVID have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2022.

      New Strong Sell Stocks for June 9th

      by Zacks Equity Research

      ALX, ACER, and SBFG have been added to the Zacks Rank #5 (Strong Sell) List on June 9, 2022.

      New Strong Sell Stocks for June 6th

      by Zacks Equity Research

      ACER, RACE, and PYPL have been added to the Zacks Rank #5 (Strong Sell) List on June 6, 2022.

      New Strong Sell Stocks for May 27th

      by Zacks Equity Research

      ACER, BBWI, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2022.

      Acer Therapeutics Inc. (ACER) Reports Q1 Loss, Misses Revenue Estimates

      by Zacks Equity Research

      Acer Therapeutics Inc. (ACER) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

      OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates

      by Zacks Equity Research

      OptiNose (OPTN) delivered earnings and revenue surprises of -29.17% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

      Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised)

      by Zacks Equity Research

      Here is how Acer Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.

      Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year?

      by Zacks Equity Research

      Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.